Abstract 470P
Background
Due to its high propensity for metastasis and lack of durable response to therapy, several biomarkers have been studied to help predict outcomes in patients with Small Cell Lung Cancer (SCLC). These biomarkers aid the clinicians in their treatment decisions among these patients. Neuron-specific enolase (NSE), can be used in supporting a diagnosis of SCLC. However, little is known on its prognostic significance due to the limited number of studies conducted. Carcino-embryonic antigen (CEA) can be used in treatment monitoring and prognostication in several cancers. Few studies have been conducted among SCLC patients investigating its prognostic significance. Moreover, no meta-analysis has been conducted on this outcome. Vascular endothelial growth factor (VEGF) plays an important role in the dissemination of malignancy. Although serum VEGF is found many cancer patients, little is known about its prognostic significance among SCLC. Moreover, no meta-analysis has been conducted on this outcome. This study aims to conduct a systematic review and meta-analysis on the prognostic significance of the CEA, NSE and VEGF on SCLC.
Methods
A systematic review was conducted to examine the prognostic significance of three biomarkers in the prognosis of SCLC: CEA, VEGF and NSE. Systematic search was done using Pubmed, Cochraine and EMBASE for articles published until July 1, 2019. Seventeen studies with a total of 3, 973 patients were included in the analysis. The primary outcome of interest was Overall Survival in SCLC. Data was summarized using RevMan 5.3. Preplanned subgroup analysis was done on the type of study and the statistic used.
Results
High CEA (HR 1.28 95%CI 1.10-1.50, p < 0.001, I2 45%) and VEGF (HR 1.84 CI 1.21-2.78 p = 0.004, I2 52%) were both associated with poor overall survival. NSE was associated with poor overall survival based on pooled retrospective studies (HR 1.42 CI 1.22-1.67, p < 0.00001, I2 34%) and prospective studies (RR 1.68 CI 1.40-2.02, p < 0.00001, I2 50%). Pooled HR for prospective studies was not significant (HR 2.32 CI 0.96-5.56, p = 0.06, I2 83%).
Conclusions
High NSE, CEA and VEGF may be used as prognostic biomarkers of poor survival in patients with SCLC. Further randomized studies may confirm these findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D.B.L. Sacdalan: Honoraria (self): Merck. All other authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract